Theodore Matejka
Psychiatric/Mental Health · Daytona Beach, FLNPI 1396742490
Payments from drug & device makers
Across 298 payments — averaging $34.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Vanda Pharmaceuticals Inc.$879
- Otsuka America Pharmaceutical, Inc.$834
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$769
- plus $4K from 21 others
What the payments were for
- Food & beverage$10,13799%
- Education$1351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 37 | $1,308 |
| AbbVie | 42 | $1,223 |
| Teva Pharmaceuticals USA, Inc. | 48 | $1,027 |
| Vanda Pharmaceuticals Inc. | 28 | $879 |
| Otsuka America Pharmaceutical, Inc. | 33 | $834 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $769 |
| Alkermes, Inc. | 23 | $730 |
| Neurocrine Biosciences, Inc. | 18 | $605 |
| AstraZeneca(2 entities) | 3 | $379 |
| Indivior Inc. | 15 | $308 |
| Gilead | 2 | $259 |
| Novo Nordisk | 2 | $221 |
| E.r. Squibb & Sons, L.L.C. | 5 | $194 |
| Axsome Therapeutics, Inc. | 2 | $154 |
| Edwards Lifesciences | 1 | $139 |
| Grifols USA, LLC | 1 | $125 |
| Idorsia Pharmaceuticals US Inc | 1 | $121 |
| Apellis Pharmaceuticals, Inc. | 1 | $120 |
| Kyowa Kirin, Inc. | 1 | $120 |
| Astellas Pharma US Inc | 1 | $112 |
| Silk Road Medical, Inc. | 1 | $104 |
| Sanofi-aventis U.S. LLC | 1 | $101 |
| Solventum Corporation | 1 | $100 |
| Esperion Therapeutics, Inc. | 1 | $96 |
| Lundbeck LLC | 4 | $92 |
| Sunovion Pharmaceuticals Inc. | 4 | $75 |
| Ceribell, Inc. | 1 | $75 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$500
- VRAYLAR$498
- INVEGA SUSTENNA$459
- Fanapt$446
- CAPLYTA$444
- LYBALVI$400
- Austedo XR$361
- INVEGA TRINZA$322
- Strensiq$267
- INGREZZA$251
- ENROUTE Transcarotid Neuroprotection System$207
- SAPIEN 3 Ultra RESILIA$139
- Livdelzi$130
- Epclusa$130
- ARISTADA INITIO$125
- Prolastin-C Liquid$125
- ABILIFY MAINTENA$124
- ABILIFY ASIMTUFII$124
- UZEDY$123
- Auvelity$121
How this compares
$10,271 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 129 | $408,545 |
| IngrezzaValbenazine Tosylate | 13 | $103,307 |
| Invega TrinzaPaliperidone Palmitate | 17 | $95,392 |
| Abilify MaintenaAripiprazole | 28 | $70,096 |
| AristadaAripiprazole Lauroxil | 24 | $69,617 |
| VraylarCariprazine Hcl | 28 | $39,244 |
| UzedyRisperidone | 11 | $33,738 |
| FanaptIloperidone | 20 | $32,159 |
| CaplytaLumateperone Tosylate | 15 | $25,062 |
| Aripiprazole | 246 | $22,014 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $20,241 |
| Risperidone ErRisperidone Microspheres | 33 | $18,548 |
| Lurasidone Hcl | 30 | $12,979 |
| Quetiapine Fumarate | 460 | $11,854 |
| Haloperidol | 375 | $10,193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $1,308 | $503,937146 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $605 | $103,30713 claims |
| Alkermes, Inc.Aristada, Lybalvi | $730 | $89,85838 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $834 | $70,09628 claims |
| AbbVieVraylar | $1,223 | $39,24428 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $1,027 | $33,73811 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $879 | $32,15920 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $769 | $25,06215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Daytona Beach
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Cheedy JajaTampa$266K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.